Multiple Sclerosis, Rituximab, Hypogamma...

In part two of this series, Dr. Shuvro Roy talks with Drs. Jiwon Oh and Amit Bar-Or about the latest developments in BTK inhibitors for MS, including safety signals, trial results, and future directions. For more information, please read about the abstract that was presented at t ... Show More

In part one of this series, Dr. Shuvro Roy talks with Drs. Jiwon Oh and Amit Bar-Or about recent multiple sclerosis clinical trial data. For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting. Read more about the Fenebrutinib Trial. ... Show More

Dr. Dara Albert talks with Dr. Jon Stone about the latest advancements in FND from the recent International Conference on Functional Neurological Disorder. Dr. Jon Stone shares insights on the field's growth, multidisciplinary care, cultural perspectives, and future directions. C ... Show More

Dr. Shuvro Roy and Dr. Annette Langer-Gould discuss the effective dose of rituximab and other B-cell depleting therapies in patients with multiple sclerosis, as well as important comorbidities to prevent infection risks. Show reference: https://www.neurology.org/doi/10.1212/NXI.0 ... Show More

Drs. Justin Abbatemarco and Géraldine Androdias discuss the impact of immune checkpoint inhibitors on the course of multiple sclerosis.  Show reference:  https://www.neurology.org/doi/10.1212/NXI.0000000000200202  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for ... Show More

Dr. Justin Abbatemarco and Dr. Aaron Zelikovich discuss the safety and efficacy of satralizumab and its role in the current treatment landscape for myasthenia gravis. Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00514-3/fulltext 

We get to the bottom of a medical mystery – what causes multiple sclerosis? A series of studies have compellingly pointed the finger at the virus behind glandular fever. We see if they stack up and assess what it means for the future of preventing and treating MS. Then nearly two ... Show More

With over 20 options, what is the best multiple sclerosis treatment for me? Selecting an appropriate disease-modifying therapy (DMT) needs to consider your risk of worsening disability over time. Your age, sex and race can affect your prognosis and can influence the power of trea ... Show More

Dr. Nara Michaelson starts a series discussing the less obvious ways that Multiple Sclerosis impacts the lives of patients and how neurologists can address these challenges and support patients. 

Like many autoimmune diseases, multiple sclerosis so clearly illustrates how detection and description of a disease only gets us so far when it comes to prevention, treatment, and cure. In the over 150 years since the first comprehensive description of multiple sclerosis, a great ... Show More

Dr. Justin Abbatemarco, Dr. Michael R. Wilson, and Dr. John Pluvinage discuss their discovery of anti-CD320 antibodies in patients with neurologic manifestations of B12 deficiency and discuss the potential implications for diagnosis and treatment.  Show reference:  https://www.sc ... Show More

<p>In this episode I cover multiple sclerosis.<br/><br/>If you want to follow along with written notes on multiple sclerosis go to <a href='https://zerotofinals.com/medicine/neurology/ms/'>https://zerotofinals.com/medicine/neurology/ms/</a> or the neurology section in the Zero to ... Show More

The latest guidelines on disease-modifying treatment in multiple sclerosis (MS) from the Association of British Neurologists is discussed in this intercontinental podcast with perspectives from the UK, the USA, and Australia.   Participants: <ul> <li>Professor Alasdair Coles is H ... Show More